Table 2 Comparison of incidence of adverse events within 28 days after different types of boost vaccination
Adverse event | All (n = 85) | Heterologous boost with Sf9 cells vaccine (n = 44) | Homologous boost with CoronaVac vaccine (n = 41) | p value |
|---|---|---|---|---|
Any adverse event, n (%) | 22 (25.88) | 9 (20.45) | 13 (31.71) | 0.279 |
Grade 1 | 17 (20.00) | 8 (18.18) | 9 (21.95) | 0.664 |
Grade 2 | 5 (5.88) | 1 (2.27) | 4 (9.76) | 0.143 |
Grade 3 or worse | 0 (0) | 0 (0) | 0 (0) | — |
Solicited adverse event within 7 days, n (%) | 17 (20.00) | 7 (15.91) | 10 (24.39) | 0.329 |
Solicited adverse event at the injection site within 7 days, n (%) | 11(12.94) | 5 (11.36) | 6 (14.63) | 0.654 |
Pain | 11 (12.94) | 5 (11.36) | 6 (14.63) | 0.654 |
Swelling | 0 (0) | 0 (0) | 0 (0) | — |
Induration | 0 (0) | 0 (0) | 0 (0) | — |
Erythema | 0 (0) | 0 (0) | 0 (0) | — |
Solicited systemic adverse event within 7 days, n (%) | 8 (9.41) | 3 (6.82) | 5 (12.20) | 0.453 |
Fatigue | 4 (4.70) | 1 (2.27) | 3 (7.32) | 0.272 |
Headache | 3 (3.53) | 1 (2.27) | 2 (4.88) | 0.515 |
Nausea | 1 (1.20) | 0 (0) | 1 (2.44) | 0.297 |
Arthralgia | 1 (1.20) | 1 (2.27) | 0 (0) | 0.332 |
Fever | 0 (0) | 0 (0) | 0 (0) | — |
Vomiting | 0 (0) | 0 (0) | 0 (0) | — |
Myalgia | 0 (0) | 0 (0) | 0 (0) | — |
Unsolicited adverse event within 28 days, n (%) | 11 (12.94) | 2 (4.55) | 9 (21.95) | 0.017 |
